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UbiquitinInsulin rapidly upregulates protein levels of PKCδ in classical insulin target tissues skeletal muscle and liver.
Insulin induces both a rapid increase in de novo synthesis of PKCδ protein. In this study we examined the
possibility that insulin may also inhibit degradation of PKCδ. Experiments were performed on L6 skeletal
muscle myoblasts or myotubes in culture. Phorbol ester (PMA)- and insulin-induced degradation of PKCδ
were abrogated by proteasome inhibition. Both PMA and insulin induced ubiquitination of PKCδ, but not of
that PKCα or PKCε and increased proteasome activity within 5 min. We examined the role of tyrosine
phosphorylation of PKCδ in targeting PKCδ for degradation by the ubiquitin-proteasome pathway.
Transfection of cells with PKCδY311F, which is not phosphorylated, resulted in abolition of insulin-induced
ubiquitination of PKCδ and increase in proteasome activity. We conclude that insulin induces degradation of
PKCδ via the ubiquitin-proteasome system, and that this effect requires phosphorylation on speciﬁc tyrosine
residues for targeting PKCδ for degradation by the ubiquitin-proteasome pathway. These studies provide
additional evidence for unique effects of insulin on regulation of PKCδ protein levels.ll Biology, Weizmann Institute
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Protein kinase C (PKC) is a family of serine/threonine kinases,
classiﬁed into three main groups [Conventional PKCs (cPKCs; α, βI,
βII, γ), Novel PKCs (nPKC; δ, ε, ν, θ,), and atypical PKCs (aPKCs; ζ, ι, λ)]
that are involved in the transduction of a number of signals important
for the regulation of cell growth, differentiation, apoptosis and
hormone responses [1–3]. The PKC isoforms differ in structure and
their dependence on various activators. The PKC proteins are believed
to remain in an inactive, cytoskeletal-associated state in the
cytoplasm; after phosphorylation, they translocate to the plasma
membrane or to membranes of cytoplasmic organelles to become
fully activated in the presence of speciﬁc cofactors [2,4,5]. Phorbol
ester stimulation of the classical and novel isoforms causes their
downregulation; stimulation of PKCδ in particular by phorbol esters or
H2O2 downregulates PKCδ via the ubiquitin-proteasome system [6,7].
We have reported that insulin stimulation of skeletal muscle
rapidly (within 1 min) tyrosine phosphorylates and activates PKCδ,
and induces its physical association with insulin receptor (IR) [8,9].
Subsequently, we found that insulin stimulation, rather than down-
regulating PKCδ, actually rapidly increases total PKCδ protein and RNA
levels on a time scale of within 5 min [10]. These effects areaccompanied by rapid activation of the PKCδ promoter and are
abrogated by pretreatment with inhibitors of either translation
(cycloheximide) or transcription (actinomycin D and DRB). During
the course of these studies, we examined the possibility that
elevations in total cytosolic PKCδ might also result from inhibition
by insulin of the rate of degradation of PKCδ. To our surprise, we found
that insulin appeared to induce a rapid increase in rate of PKCδ protein
degradation with approximately the same time course as the increase
PKCδ protein.
Several studies indicate that insulin and other growth factors are
important regulators of protein synthesis via both increased protein
synthesis and inhibition of protein degradation [11–13]. It is generally
accepted that insulin has an inhibitory effect on protein degradation
and appears to partially inhibit the degradation of both short-lived
and longer-lived proteins through Insulin Degrading Enzyme (IDE),
which can inhibit the proteasomes, thus decreasing cytosolic protein
degradation. In addition, insulin has been reported to increase
degradation of insulin receptor (IR) and IRS proteins in 3T3
adipocytes, FAO hepatoma cells, and adipocytes in normal rats and
humans (see [14–16]). This effect occurs with a time course of 4–12 h.
Similarly, aldosterone was reported to increase degradation of IR and
IRS proteins in vascular smooth muscle cells and adipocytes, again
with a time course of several hours [17,18]. Effects of insulin to
promote or increase rapid protein degradation have not been
reported. In this study, we have examined the mechanisms by
which insulin rapidly increases degradation of PKCδ in insulin target
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insulin induces a rapid ubiquitination of PKCδ, but not PKCα or ε, and
this targets PKCδ for degradation by the proteasomes.
2. Materials and methods
2.1. Materials
Tissue culture media and serum were purchased from Biological
Industries (Beit HaEmek, Israel). Enhanced chemical luminescence
(ECL) was performed using antibodies purchased from BioRad
(Hercules, CA, USA) and other reagents from Sigma (St. Louis, MO,
USA). The following antibodies were used: anti-PKCδ, anti-PKCα and
anti-PKCε (Santa Cruz Biotechnology); anti-skeletal muscle β-actin
(Sigma Chemicals); Anti-FLAG M2 (Sigma); Anti-ubiquitin (Santa
Cruz Biotechnology); Horseradish peroxidase-conjugated anti-rabbit
and anti-mouse IgG (Bio-Rad). HA-tagged ubiquitin plasmidwas a gift
from Dr. Haim Cohen, Bar-Ilan University; Leupeptin, aprotinin, PMSF,
DTT, orthovanadate, and pepstatin were purchased from Sigma
Chemicals. Insulin (HumulinR—recombinant human insulin) was
purchased from Lilly France SA (Fergersheim, France).
2.2. Preparation of skeletal muscle cell cultures
L6 myoblasts (obtained from Prof. Nava Bashan, Soroka Medical
Center, Ben-Gurion University) were prepared as described [10,19].
Cells were maintained in Modiﬁed Eagles Medium-Alpha (MEM)
containing 10% Fetal Calf Serum (FCS) and 22 mM glucose. Cultures
were incubated in a water-saturated atmosphere of 95% air and 5%
CO2 at 37 °C. The medium was changed every 2–3 days. L6 myoblasts
spontaneously differentiate upon reaching conﬂuence, when they
fuse to form multinucleated mature myotubes within 10 days in
culture. Mature myotubes were transferred to low glucose (5 mM),
serum free medium 18 h before study.
3. Section on preparation of primary cultures removed
3.1. Preparation of cell lysates
Culture dishes containing the muscle cells were washed with
Ca+2/Mg+2 free PBS and then mechanically detached in RIPA
buffer containing cocktails of proteases and phosphatase inhibitors.
After 30 min on ice, the preparation was centrifuged at 20,000g for
20 min at 4 °C. The supernatant was used for immunoprecipitation,
and expression studies.
3.2. Immunoprecipitation
To 300 μl of cell lysate, 25 μl of A/G Sepharose was added and the
suspension was rotated continuously for 30 min at 4 °C. The
preparation was then centrifuged at 20,000g at 4 °C for 10 min.
Speciﬁc antibodies to the appropriate proteins (dilution 1:100) were
added to the supernatant, and the mixture was rotated continuously
for 60 min at room temperature. Next, 30 μl of A/G Sepharose was
added to the suspension, which was then rotated overnight at 4 °C.
The suspension was then centrifuged at 20,000g for 2 min and the
pellet waswashed twicewith RIPA buffer, and oncewith PBS (without
Ca+2, Mg+2). The immunoprecipitate was mixed with 25 μl of sample
buffer. The suspension was again centrifuged at 15,000g (4 °C for
10 min), boiled for 5 min and subjected to SDS-polyacrylamide gel
electrophoresis (PAGE).
3.3. Protein assay
Protein concentration in samples was determined with DC Protein
Assay kit purchased from Bio-Rad, as already described [10,19,20].3.4. Western blot analysis
Samples containing 20–25 μg proteinwere electrophoresed through
SDS-polyacrylamide gels (7.5–10%) and electrophoretically transferred
onto Immobilon-P membranes in DUNN transfer buffer overnight at
4 °C. Following transfer, the membranes were subjected to blocking
solution for 60 min. Membranes were then incubated with speciﬁc
antibodies overnight at 4 °C. The membranes were washed four times
for 15 min in TBST and then further incubated for 60 min at room
temperature with horseradish peroxidase-labeled secondary antibody
diluted 1:10,000 in blocking solutions without sodium azide. After four
15-minwashes in TBST, themembraneswere treatedwith ECL reagents
for 1 min and then exposed on Fugi X-ray ﬁlm for the required times
(30–90 s). The correct bandswere identiﬁedby runningpre-stained SDS
PAGE standards (marker) with known molecular weights.
3.5. PKC isoform viral infection
Following differentiation of cultured rat muscle intomyotubes, the
culture medium was aspirated and cultures were infected with the
viral medium containing PKCδ, or control vector recombinant
adenoviruses for 1 h as described [9,21]. The cultures were then
washed with DMEM and transferred to growth medium. Cells 24 h
post infection were transferred to serum free medium for 18 h.
Control and insulin-treated cultures were used for experiments.
3.6. Transfection of cell cultures
Transfection of L6myoblasts was accomplished using Lipofectamine
reagent (Invitrogene) according to manufactures protocol. 24 h after
transfection cells were transferred to serum-free medium after which
treatment was applied to cultures.
3.7. Proteasome activity assay
Culture dishes containing the L6 cells at 80%–90% conﬂuence were
appropriately treated, washed 2× with PBS and mechanically detached
with Ca+2/Mg+2 free PBS. Next, cells were centrifuged at 5000g at 4 °C
for 5 min and homogenized. Lysates were incubated with 13 μM of the
ﬂuorogenic proteasome substrate N-Succinyl–Leu–Leu–Val–Tyr-7–
Amido-4–Methylcoumarin for 1 h at 25 °C with shaking after which
time ice-cold ethanol (100%)was added, and the sampleswere analyzed
by a HPLC system LaChrom D-7000 (Merck Hitachi) utilizing a FL
detector L-7480. Data acquisition was performed by the HSM software
and further analyzed by Microsoft Excel.
3.8. Protein degradation
Degradation of PKC proteins was performed as already de-
scribed [10]. Brieﬂy, L6 cells were transferred to low glucose,
serum-free medium for 3 h, following which they were incubated
with 35S-methionine (50 μCi/ml) for 4–5 h to label endogenous
proteins. The cells were washed 3 times with PBS to remove excess
labeled methionine and transferred to growth medium containing
2 mM methionine to reduce reuptake of 35 S-methionine released
from degraded proteins. The cells were then stimulated with
insulin for 5–30 min, lysed and the appropriate PKC isoform was
immunoprecipitated with speciﬁc antibodies against PKCs α, δ or ε.
The immunoprecipitated PKC isoform was subjected to SDS-PAGE
and then autoradiography for 7–10 days.
4. Results
In initial experiments we re-examined the effects of insulin on
PKCδ levels. As we have shown that insulin also stimulates PKCα
[22,23] and PKCε (Inbar, Horovitz-Fried and Sampson, unpublished),
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[24,25], we compared the effects of insulin and PMA on levels of these
isoformswith those PKCδ. We earlier reported that insulin stimulation
of not only activates PKCδ but also rapidly upregulates its expression
and availability [10]. Here, we conﬁrmed this effect (Fig. 1A and D)
and also found that insulin induces a rapid increase in levels of PKCsα
(Fig. 1B, E) and ε (Fig. 1C, F). These results were observed in L6
myoblasts, L6myotubes, as well as in rat skeletal myotubes in primary
culture.
Administration of phorbol esters results in downregulation of
classical and novel PKC isoforms, beginning within a few hours and
leading to barely detectable levels after 24 h.We, therefore, compared
effects of PMA with those of insulin over 24 h on levels of PKCs δ, α
and ε. As seen in Fig. 2, PMA stimulation produced a detectable
decrease in protein levels of each of the 3 isoforms within 1–3 h, and
an almost complete disappearance within 24 h. Insulin stimulation,
however, did not cause any detectable downregulation of either these
isoforms. One obvious mechanism for the lack of downregulation of
these isoforms by insulin might be inhibition of their degradation.
Although we have reported that insulin appeared to increase the rate
of degradation of PKCδ, we re-examined this effect and compared
responses of PKCδ to those of PKCs α and ε, which are also not
downregulated by insulin.
4.1. Degradation of pre-existing PKCδ, but not that of PKCs α and ε, is
increased by insulin
The rate of degradation of pre-existing PKC was determined in 2
ways. In one, we pre-treated cells with cycloheximide (Chx; 1 mM, 3–
4 h) in order to inhibit insulin-induced increase in PKC protein
(Fig. 1), and then followed PKC protein levels in response to insulin as
in Fig. 1. In the second, we pre-labeled PKCs with 35S-methionine for
4–5 h, and then stimulated the cells with insulin and followed the 35S-Ins (min) 0 5 15
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Fig. 1. Insulin rapidly upregulates PKCδ (A, D), PKCα (B, E) and PKCε (C, F) protein levels. L6
glucose serum-free medium for 18 h as described in Materials and methods. Following treat
PAGE and immunoblotting (A–C) with appropriate anti-PKC or anti-actin antibodies. The gra
each bar representing the mean±s.e. of measurements from 3 to 5 separate experiments.methionine labeled PKC levels as described in Materials and methods.
The results of studies of the effects of Chx on protein levels of PKCs δ
and α are shown in Fig. 3. As a consequence of pre-treating cells with
Chx, insulin stimulation caused PKCδ protein levels to decrease rather
than increase (as in control cells (Fig. 2A, B). In contrast, pre-
treatment with Chx did not result in an insulin-induced decrease
PKCα protein levels; indeed, these appeared to increase (Fig. 3C, D).
The results regarding PKCε (not shown) were similar to those of PKC
α. In the second series of experiments, we conﬁrmed our earlier
report [10] that 35S-methionine-labeled PKCδ decreases relatively
rapidly in the absence of insulin during 5–30 min (Fig. 4A, lanes 2, 4
and 6). Insulin stimulation increases the rate of degradation (lanes 3, 5
and 7). In contrast, following insulin stimulation the amount of 35S-
methionine-labled (pre-existing) PKCα (Fig. 4B,E) and PKC ε (Fig. 4C,
F) was greater (lanes 3, 5 and 7) than that in non-stimulated cells
(lanes 2, 4 and 6). Thus, in contrast to PKCδ, PKCs α and ε do not
appear to be rapidly degraded by insulin.
4.2. Insulin-induced PKCδ degradation involves the ubiquitin-
proteasome system
Downregulation of PKC following activation by phorbol esters has
been shown to occur as a result of degradation via the ubiquitin-
proteasome system [25]. Accordingly, we next examined the possible
involvement of the ubiquitin-proteasome system in the rapid
degradation of PKCδ in response to insulin. We ﬁrst studied regulation
of basal levels of PKCδ by treating cells with inhibitors of both calpain
and proteasomes for 24 h and then examined the basal levels of PKCδ
protein. We also studied effects of inhibitors of proteolytic enzymes
such as calpains, which were found to be involved in diabetes. We
treated cells with the proteasome inhibitor MG132, the combined
calpain and proteasome inhibitor ALLN, and the selective calpain
inhibitor ALLM. Fig. 5A shows that 24 h treatment of non insulin-0
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(10−7 M) for the times indicated, cell lysates were subjected to SDS/PAGE and immunoblotting with appropriate anti-PKC or anti-actin antibodies. (A–C) PMA downregulates PKCs
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1269C. Brand et al. / Biochimica et Biophysica Acta 1803 (2010) 1265–1275stimulated cells with MG132 caused a decrease in PKCδ (78 kDa) and
led to an increase in the cleaved form of PKCδ (50 kDa). Treatment
with inhibitor ALLN, but not ALLM, also led to a slight appearance of
cleaved PKCδ. These data suggest that regulation of basal levels of
PKCδ involves mainly the ubiquitin-proteasome system.
To investigate this possibility further, we treated cells with MG132
prior to addition of insulin and measured PKCδ protein levels. We
reasoned that PKCδ levels following insulin stimulation would be
increased in cells pretreated with MG132 compared to control cells.
The effects of proteasome inhibition on PKCδ protein in response to
insulin were compared to those following stimulation with PMA. In
control cells PMA stimulation caused amarked decrease in PKCδ levels
by 3 h and nearly complete disappearance by 24 h. In cells pretreated
with MG132, PKCδ levels after 3 and 6 h after PMA were essentially
unchanged from control and were still detectable after 24 h,
conﬁrming that PMA-induced downregulation of PKCδ involves the
ubiquitin-proteasome pathway. In contrast, insulin stimulation of
control cells (as already shown) caused PKCδ protein levels to
increase by 15 min and the levels remained elevated for up to 2 h
(Fig. 5C, Control). To our surprise, this effect was not detectably
altered by pretreatment of cells with MG132 alone (Fig. 5C, MG132,
and Fig. 5D).
One possible explanation for the lack of any noticeable increase
in PKCδ protein in response to insulin following treatment with
MG132 compared to control might be that the rapid degradation
might be masked by the closely time-linked increase in PKCδ
synthesis (Figs. 1A and 2A). Accordingly, we next attempted to
distinguish between the two processes—rapid transcription/transla-
tion on the one hand and rapid degradation on the other hand. Inthis series of experiments, we ﬁrst inhibited protein synthesis by
treatment of cells cycloheximide (Chx) for 3 h, and then we treated
or not with MG132 for 1 h prior to stimulation with insulin. PKCδ
protein levels were measured during the ﬁrst 15 min of insulin
stimulation, since this is the time course of the rapid increase in
insulin-induced PKCδ synthesis. The results are summarized in
Fig. 5D and E. In control cells, insulin induced an increase in PKCδ
levels, as described. In cells pre-treated with Chx, insulin stimulation
decreased PKCδ protein levels consistent with the notion that the
rapid increase in synthesis masked the increase in degradation.
Finally, in cells treated with ﬁrst Chx and then MG132, the insulin-
induced decrease in PKCδ protein levels seen in Chx-treated cells
was completely abrogated.
To further examine the possibility that insulin-induced degrada-
tion of PKCδmay indeed bemediated by the proteasomal pathway, we
examined effects of MG132 directly on the effects on insulin to
increase degradation of preformed 35Smethionine-labeled PKCδ (as in
Fig. 4A). An example of results obtained in these experiments is
shown in Fig. 6A. 35S-methionine-labeled PKCδ increased slightly in
MG132-treated cells (lane 2 vs. lane 4) compared to untreated cells
(lane 1 vs. lane 3), indicating that the proteasome system may be
involved in basal turnover of PKCδ. As shown previously, insulin
stimulation of the cells increased the rate of degradation, the amount
of 35S-methionine-labled PKCδ being lower in insulin-stimulated cells
(lane 5) than the unstimulated cells (lane 3). This decrease in labeled
PKCδ was abrogated by pretreatment with proteasome inhibitor
MG132 (lane 6). These studies strongly support the idea that insulin-
induced degradation of PKCδ directly involves the proteasome
pathway.
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Fig. 5. Regulation of PKCδ degradation involves the ubiquitin-proteasome system. L6 skeletal muscle cells were prepared and grown in culture as described in Fig. 1. (A) Western
blots showing effects of calpain or proteasome inhibitors on basal levels of PKCδ. Cells were treated with MG132 (10−6 M), ALLN (10−5 M) or ALLM (100−4 M) for 24 h following
which cell lysates were prepared and subjected to SDS/PAGE and immunoblotted with speciﬁc anti-PKCδ or anti-actin antibodies. (B and C)Western blots showing effects of MG132
on levels of PKCδ following stimulation by PMA or Insulin. Cells were treated with MG132 (10 μM) for 1 h and then stimulated with 10−7 M PMA (B) or 10−7 M insulin (C) for the
times indicated. Western blotting as in A. (D) Graph of densitometry measurements made on Western blots (as in C) from 3 separate experiments. Each bar is the mean±s.e. of
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protein synthesis and proteasomes are inhibited. L6 skeletal muscle cells were treated or not (Con) with cycloheximide (Chx 10−3 M) for 3 h, and then treated or not with MG132
(10 −6 M) for 1 h before stimulation with insulin (10−7 M) for the times indicated. (E) Western blots of PKCδ protein; (F) graph of densitometry measurements made on Western
blots (as in E) from 3 separate experiments. Each bar is the mean±s.e. of measurements normalized to actin levels. (*Pb0.01).
1270 C. Brand et al. / Biochimica et Biophysica Acta 1803 (2010) 1265–12754.3. Insulin increases proteasome activity
We next examined the possibility that insulin treatment of the
cells may stimulate proteasome activity (see Materials and methods).
Fig. 6B shows that insulin induces a measurable and signiﬁcant
increase in proteasome activity within 5 to 30 min of addition to the
cells. The insulin-induced increase in proteasome activity does not
occur as a result of increased proteasome expression, as shown by
Western blotting with a speciﬁc antibody corresponding to a section
of C-terminal proteasome 20S subunit C2 (Fig. 6C).
4.4. Insulin induces PKCδ-ubiquitin association
Prior to degradation by the proteasomes, certain cellular proteins
undergo binding to ubiquitin, thereby targeting them for degradation.
To investigate this, we immunoprecipitated PKCδ from whole cell
lysates of PMA- and insulin-stimulated cells with speciﬁc anti PKCδ
antibodies and, following SDS-PAGE, probed with speciﬁc anti-ubiquitin antibodies to reveal ubiquitinated PKCδ. In these experi-
ments, typical “smears” were obtained on immunoprecipitated PKCδ
blotted with anti-ubiquitin antibodies. Fig. 7A and C show that insulin
and PMA increase association of PKCδ with ubiquitin within 5 min of
stimulation; the 2 remain associated for at least 30 min.
We next examined effects of MG132 on insulin-induced associa-
tion between PKCδ and ubiquitin. Following pretreatment of cells
with MG132 for 1 h, insulin-induced association of PKCδ with
ubiquitin was increased (Fig. 7B). In contrast, neither PKCα nor
PKCε, which are not rapidly degraded by insulin, was ubiquitinated in
response to insulin stimulation (Fig. 7D, E).
4.5. Phosphorylation of PKCδTyr311 is important in insulin-induced
activation of proteasomes and PKCδ degradation
Phosphorylation on speciﬁc tyrosine residues is a major factor
determining the activity and function of PKCδ. One of the residues on
which PKCδ is phosphorylated is Tyr311 located in the hinge region.
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phorbol esters and H2O2 [6,7,26]. The importance of the Tyr311 site in
insulin-stimulated skeletal muscle has yet to be determined.
Accordingly, we examined the possibility that phosphorylation of
Tyr311 may be involved in insulin-induced degradation of PKCδ in L6
skeletal muscle cells. We ﬁrst determined that insulin does, indeed,
phosphorylate Tyr311 in L6 cells. An example is shown in Fig. 8A in
which effects of insulin are compared with those of PMA. Both insulin
and PMA induced phosphorylation of Tyr311, the effect beginning as
early as 2 min and continuing for up to 15 min, the longest time
studied. The increase in phosphorylated Tyr311 in response to insulin
when normalized to total PKCδ protein levels was highly signiﬁcant.
In order to further study the importance of the Tyr311site in
insulin-induced proteasome activation and degradation of PKCδ, we
expressed mutated (tyrosine to phenylalanine-PKCδY311F) in L6
myoblasts because of the greater ease and efﬁciency of transaction
than obtained with myotubes. L6 myoblasts have been shown to be
useful models for various aspects of insulin signaling in skeletal
muscle [27,28]. We have previously shown that insulin effects on
PKCδ protein levels and signaling to glucose uptake in myoblasts are
essentially indistinguishable from that in myotubes [10,29]. The
Y311F mutant is not phosphorylated. The three plasmids used(control vector-CV; wild type PKCδ-WT; and mutated-PKCδY311F)
were tagged with a FLAG tag to distinguish between endogenous and
exogenous proteins. Expression levels of WT PKCδ and the mutant
PKCδY311F are shown in Fig. 8C (the left blots are plasmid
transfection and the right blots are viral infection). In a series of
studies we found that expression of the PKCδY311F mutant did not
alter the morphology of L6 cells, or their responses to insulin e.g.,
translocation to membranes, IR signaling, phosphorylation of Akt on
either the threonine or serine sites, basal and insulin-stimulated
glucose uptake (data available on request).
We next examined the effect of Y311F on insulin-induced
ubiquitination of PKCδ. Cells expressing the control vector were
compared to cells over expressing wild type and mutated PKCδ. Two
sets of experiments were preformed. The ﬁrst was done on L6
undifferentiated myoblasts. 24 h post transfection, PKCδ was immu-
noprecipitated from whole cell lysates and, o following SDS-PAGE,
were probed with speciﬁc anti-PKCδ and anti-ubiquitin antibodies.
The results of these studies are presented in Fig. 8D. Insulin-induced
conjugation of ubiquitin to PKCδY311F was strongly reduced
compared to WTPKCδ. The second set of experiments was done on
differentiated, mature L6 myotubes infected by adenoviral constructs
expressing the relevant mutations (Fig. 8E). Similar results were
obtained, namely insulin-induced ubiquitination of PKCδY311F was
markedly less than that of WTPKCδ. Thus, over expression of mutated
PKCdeltaY311F exerted a dominant negative effect and nearly
completely abrogated insulin-induced ubiquitination of PKCδ.
We also performed reciprocal experiments in which detection of
the ubiquitinated PKCδ was done on immunoprecipitates prepared
from cells co-transfected with a plasmid encoding an HA-tagged
ubiquitin. HA-tagged ubiquitin was immunoprecipitated from whole
cell lysates of CV-, PKCδY311F- and WTPKCδ-transfected cells with
anti-HA antibodies. Levels of ubiquitinated PKCδ were detected by
immunoblotting with anti FLAG antibodies. Results are presented in
Fig. 8F. Ubiquitination ofWTPKCδ both in the basal state and following
insulin stimulation was higher than that of PKCδY311F. Ubiquitinated
PKCδ is larger than PKCδ that is not bound to ubiquitin and, therefore,
appears higher on the gel (around 95–100 kDa) than normal
(76 kDa). Whereas it would appear that PKCδ is poly-ubiquitinated,
the typical smear of poly ubiquitination was not apparent on the gel.
However, poly-ubiquitination requires the attachment of at least four
ubiquitin molecules (adding an approximately 30 kDa to PKCδ). Thus,
the appearance of PKCδ at around 100 kDa indicates that PKCδ may
be either poly-ubiquitinated or multi-ubiquitinated, i.e. mono/di-
ubiquitin molecules bound to distinct sites of PKCδ. When immuno-
blotted with an antibody against HA-tagged ubiquitin, lysates from
the cells displayed the typical ubiquitin smear (not shown).
It was next important to establish if phosphorylation on Tyr311 is
essential for proteasome activation. To examine this, we measured
proteasome activity in cells expressing the different PKCδ constructs.
These data are shown in Fig. 9. Proteasome activity was increased
four-fold by insulin in cells over expressing WTPKCδ. In contrast, in
cells over-expressing PKCδY311F, the effect of insulin to increase
proteasome activity was hardly detectable. Thus, similar to its effect
on PKCδ ubiquitination, the PKCδY311F mutant appeared to have a
dominant negative effect on insulin-induced proteasome activity.
4.6. Phosphorylation of PKCδ on tyrosine 311 is essential for PKCδ
degradation
As we have shown, PKCδ is degraded following activation by both
PMA and insulin. Both substances also phosphorylate the Tyr311
residue. We next examined the possibility that phosphorylation of
Tyr311 is indeed a modiﬁcation that destabilizes the enzyme and
promotes down-regulation. Cells were transfected with FLAG-tagged
control vector, WTPKCδ and PKCδY311F. Cells were then treated with
insulin or PMA for 3 to 24 h, lysed, submitted to SDS-PAGE and
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antibodies. We then determined levels FLAG-tagged WTPKCδ and
PKCδY311F in response to PMA and insulin stimulation in order to
distinguish between the exogenous, preformed PKCδ and the PKCδ
that is newly synthesized as a result of insulin treatment. First, levels
of total PKCδ protein were examined in cells transfected with the
control vector (CV). Fig. 10A shows that there is a marked difference
between total PKCδ protein levels following insulin and PMA
treatment. As expected, PMA stimulation induced downregulation
of the enzyme within 3 h, whereas insulin stimulation induced an
increase in PKCδ protein levels. Next, the levels of exogenous, FLAG-
taggedWTPKCδwere examined in response to insulin and PMA using
speciﬁc anti-FLAG antibodies (Fig. 10B). Both insulin and PMA
stimulation induced a gradual decrease of FLAG-tagged WTPKCδ.
This indicates that the existing PKCδ protein was degraded in
response to insulin. Finally, the levels of exogenous, FLAG-tagged
PKCδY311F were examined in response to insulin and PMA using
speciﬁc anti-FLAG antibodies (Fig. 10C). Levels of PKCδY311F increase
in response to both PMA and insulin treatment. Thus, PKCδY311F is
not degraded in response to insulin, indicating that the Tyr311 is a
crucial site for regulating the degradation of PKCδ.
5. Discussion
In the current study, we have shown that insulin-activated PKCδ is
bound to ubiquitin and targeted to the proteasomes for degradation.
This effect occurs nearly co-incident with the effect of insulin to
induce a rapid de novo synthesis of PKCδ protein [10]. These nearly
simultaneous effects appear to result in a “stable” pool of PKCδ to be
available in the IR signaling cascade. The pattern of insulin effect
(synthesis and degradation) is unique for PKCδ among the PKC
isoforms. Thus, whereas following stimulation of skeletal muscle by
insulin, protein levels of PKCsα and εwere not downregulated, but no
effects on degradation of these isoforms by insulin were detected. This
is in contrast to the effect of phorbol esters (PMA), which are known
to downregulate classical and novel PKC isoforms. Indeed, our results
suggest that insulin may prevent PKCs α and ε from rapidlyassociating with ubiquitin and being subsequently targeted to the
proteasomes, thereby delaying or inhibiting their degradation. In
examining the mechanisms underlying this unique effect of insulin on
PKCδ degradation, we found that insulin induces a rapid onset series
of effects including association of PKCδwith ubiquitin and an increase
in proteasome activity. Finally, we found that phosphorylation of
tyrosine311 is essential for insulin-induced ubiquitination of PKCδ, for
increased proteasome activity, and for PKCδ degradation. Thus, there
appears to be a unique and exclusive relation between insulin
stimulation of PKCδ and its subsequent degradation, as there is
regarding insulin-induced association of PKCδ with IR and increased
PKCδ transcription and translation leading to elevated PKCδ protein
levels [10,20]. It has long been recognized that activation of PKC
isoforms by physiological or non physiological agents [30,31]
ultimately leads to down-regulation of the enzyme through post-
transcriptionalmechanisms. This is not the case, however, with regard
to insulin stimulation of PKs δ, α, and ε.
Numerous studies show that the major effect of insulin on protein
metabolism in the adult animal is inhibition of protein degradation, and
not acceleration. It was shown that Insulin Degrading Enzyme (IDE) is
involved in cellular insulinmetabolism, and that insulin inhibits protein
degradation via an interaction with IDE [11–13]. Thus, insulin-induced
proteasome inhibition may involve the generation of inhibitory
fragments of insulin, or displacement of IDE from the proteasomes.
Other studies, including some performed on L6 myotubes, report that
insulin inhibits degradation of long-lived proteins but not of short-lived
proteins [11]. Insulin also induces degradation of IRS-1, but this
degradation occurs with treatment over a 4- to 12-h period [14–16].
Our studies showed that treatment of non-stimulated skeletal muscle
cells with cycloheximide resulted in a rapid (within 30 min) decrease in
PKCδ protein levels, indicating that this PKC isoform is a short-lived
protein with a rapid turnover rate [10].
This study is the ﬁrst to demonstrate that insulin rapidly increases
the rate of PKCδ protein degradation speciﬁcally as a result of its
activation. These ﬁndings are in accord with those showing that
degradation of PKCs α, δ and ε is dependent upon kinase activity, and
that pharmacologic blockade of PKCs partly prevents their
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tyrosine phosphorylation) leading to stimulation of catalytic activity. It,
thus,may be possible that effects of PMA and insulin action on PKCprior0
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Fig. 9. Insulin does not increase proteasome activity in PKCδY311F (δY311F)-
transfected cells. L6 skeletal muscle cells were prepared and grown in culture as
described in Fig. 1. L6myoblasts were transfected with control empty vector (CV), WTδ,
or δY311Fmutant. 24 h post-transfection, cells were treated with 10−7 M insulin for the
times indicated. Cell lysates were prepared and assayed for proteasome activity as
Fig. 6B. Each bar is the mean±s.e. of measurements on 3 replicates in each of 3
experiments. (*Pb0.05; **Pb0.01).to increased catalytic activity may be important in regulation of PKCδ
protein expression. Further studies are clearly required on this point.
Our studies do not rule out the possibility that both the calpain and
the ubiquitin-proteasome systems may be involved in regulation of
PKCδ degradation. Under basal conditions, treatment with MG132
decreased total PKCδ and the appearance of the cleaved form of PKCδ,
probably the catalytic and regulatory fragments of the enzyme.
Treatment with inhibitor ALLN, but not ALLM, also led to a slight
appearance of cleaved PKCδ. This might be due to cleavage by a large
amount of circulating calpains and caspases whose degradation by the
proteasomes may be inhibited as well (see [15]), since PKCδ is
proteolytically cleaved by caspase-3 following exposure to protea-
some inhibitor MG-132 [32]. Inhibition of calpains by ALLN and ALLM
did not produce the cleaved form of PKCδ. In contrast, other studies
report the accumulation of Akt/PKB and IR, which do not have
cleavage sites, in response to MG132. In skeletal muscle cells, protein
degradation occurs by lysosomal and nonlysosmal pathways, and
studies have reported an inhibitory effect of insulin on lysosomal
protein degradation, which is seen primarily in severe catabolic
conditions such as total insulin deﬁciency (see [33]). In addition, the
calcium activated-proteases, calpains, have been implicated in
diabetes [34], skeletal muscle protein degradation [35,36], and PKC
signal transduction [37]. Downregulation of PKC isoforms α δ and ε in
response to tumor-promoting phorbol esters is via the ubiquitin-
proteasome pathway [36]. It was also reported that at least two
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Fig. 10. Insulin-induced degradation of PKCδ protein requires phosphorylation of Tyr311. L6 skeletal muscle cells were prepared and grown in culture as described in Fig. 1. L6 myoblasts
were transfectedwith control vector (A),WTδ, (B) or δY311F (C)mutant vectors. Cells were treatedwith 10−7 M insulin or 10−7 M PMA for the times indicated. (A–C)Whole cell lysates
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single PKC agonist can activate both pathways at the same time [38].
Our results suggest that insulin's effect on proteasome activitymay
actually be due to activated PKCδ, which is targeted to the
proteasomes in association with ubiquitin. Thus, in cells over-
expressing PKCδY311F, both binding of PKCδ to ubiquitin and the
effect of insulin on proteasome activity were strongly inhibited. As a
consequence, insulin-induced degradation of PKCδ was also abrogat-
ed. This indicates that tyrosine phosphorylation of PKCδ, one of the
earliest events occurring in response to insulin in skeletal muscle
[8,9], particularly on tyrosine311, plays an important role in insulin-
induced degradation of PKCδ. Tyr311 of PKCδ has been shown to be
phosphorylated in response to a variety of stimuli including oxidative
stress [6,7], angiotensin [39], ceramide [40], and PMA [41]. We found
that the Tyr311 residue of PKCδ is also phosphorylated in response to
insulin stimulation. We propose that phosphorylation on PKCδTyr311
(by itself or in conjunction with a subsequent modiﬁcation) induces a
conformational change in PKCδ that exposes an otherwise hidden
optimal ubiquitination site. The PKCδY311F mutant (no phosphory-
lation at the 311 site) renders it resistant to insulin-induced
degradation. Over-expression of the PKCδY311F also reduced insu-
lin-induced proteasome activity. This indicates that ubiquitination is
required for proteasomal PKCδ degradation, and that insulin-induced
ubiquitination of PKCδ targets it for degradation by the proteasome
system. Our ﬁndings are compatible with those [42] showing that
C2C12 myotubes transfected with a constitutively active PKCα vector
showed increased proteasome activity over a longer time course in
response to PIF, compared with their wild-type counterparts. In
contrast, myotubes transfected with a dominant-negative, kinase
inactive, PKCα exhibited no increase in proteasome activity at any
time point.In conclusion, we have shown that insulin uniquely induces a rapid
degradation of PKCδwith a similar time course to the increase in PKCδ
protein synthesis. This degradation occurs via the ubiquitin-protea-
some system and appears to play a role in the regulation of PKCδ
protein levels. This further attests to the unique relation between
insulin, insulin receptor and PKCδ in the regulation of IR signaling.
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